Drugs / Debio 1347
Debio 1347
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01948297 | Aug 2013 → Jun 2020 | cancer | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03344536 | Nov 2017 → Aug 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03834220 | Mar 2019 → Dec 2020 | cancer | Debiopharm International SA | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Debio 1347 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03834220 ↗ |
| Action | Inhibit | “Oral Selective Pan-FGFR Inhibitor Debio 1347” NCT03834220 ↗ |
| Route | Oral | “Debio1347 orally administered daily” NCT01948297 ↗ |
| Target | FGFR1 | “A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3” NCT03834220 ↗ |
| Target | FGFR2 | “A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3” NCT03834220 ↗ |
| Target | FGFR3 | “A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3” NCT03834220 ↗ |